Document Detail


Androgen deficiency and atherosclerosis: The lipid link.
MedLine Citation:
PMID:  19818414     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The relationship between androgen deficiency and atherosclerosis is complex, poorly understood, and remains controversial. The aim of this review is to evaluate the data in the literature to determine if androgen deficiency modulates lipid profiles and contributes to atherosclerosis development or progression. Studies in animals and humans suggest that androgen deficiency is associated with increased triglycerides (TGs), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C). Although the effects of androgen deficiency on high-density lipoprotein cholesterol (HDL-C) remains controversial, recent data suggest that androgen therapy is associated with increased levels of HDL-C and may improve reverse cholesterol transport. Animal studies suggested that androgen deprivation adversely affect lipid profiles and this was reversed by androgen treatment. Furthermore, androgen treatment of hypogonadal men significantly improved lipid profiles. Emerging data indicate that androgens play an important role in lipid metabolism. Therefore androgens are critical in the prevention and progression of atherosclerosis. Androgen deficiency contributes to increased TGs, TC, LDL-C and reduced HDL-C while androgen treatment results in a favorable lipid profile, suggesting that androgens may provide a protective effect against the development and/or progression of atherosclerosis.
Authors:
Abdulmaged M Traish; Rami Abdou; Kyriakos E Kypreos
Related Documents :
10545674 - Effect of antioxidant vitamin e as a protective factor in experimental atherosclerosis ...
323454 - An in vivo comparison of chlorhexidine and picloxydine mouthrinses: a possible associat...
19029274 - Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus e...
2311094 - Experimental obstructive coronary atherosclerosis in the hyperlipidemic hamster.
20200254 - Zinc bioavailability and homeostasis.
7768584 - Salt-induced increases in systolic blood pressure affect renal hemodynamics and protein...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2009-10-06
Journal Detail:
Title:  Vascular pharmacology     Volume:  51     ISSN:  1879-3649     ISO Abbreviation:  Vascul. Pharmacol.     Publication Date:    2009 Nov-Dec
Date Detail:
Created Date:  2009-11-16     Completed Date:  2010-01-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101130615     Medline TA:  Vascul Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  303-13     Citation Subset:  IM    
Affiliation:
Department of Biochemistry and Urology, Boston University School of Medicine, Boston, MA 02118, USA. atraish@bu.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Androgen Antagonists / adverse effects
Androgens / deficiency*
Animals
Apolipoproteins E / deficiency
Atherosclerosis / epidemiology,  etiology*
Cholesterol, HDL / blood
Humans
Lipoproteins / metabolism
Male
Prostatic Neoplasms / drug therapy
Testosterone / blood
Chemical
Reg. No./Substance:
0/Androgen Antagonists; 0/Androgens; 0/Apolipoproteins E; 0/Cholesterol, HDL; 0/Lipoproteins; 58-22-0/Testosterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Zebrafish (Danio rerio) androgen receptor: Sequence homology and up-regulation by the fungicide vinc...
Next Document:  CpG ODN pretreatment attenuates concanavalin A-induced hepatitis in mice.